Antares Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Antares Pharma's estimated annual revenue is currently $63.6M per year.
- Antares Pharma received $46.0M in venture funding in May 2015.
- Antares Pharma's estimated revenue per employee is $683,376
- Antares Pharma's total funding is $45M.
Employee Data
- Antares Pharma has 93 Employees.
- Antares Pharma grew their employee count by -22% last year.
Antares Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.6M | 21 | -9% | N/A | N/A |
#2 | $7.5M | 147 | 8% | N/A | N/A |
#3 | $7.2M | 22 | -27% | N/A | N/A |
#4 | $4180M | 13825 | 1% | $550M | N/A |
#5 | $9.4M | 51 | 13% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $8M | 39 | 8% | N/A | N/A |
#8 | $9.2M | 42 | 5% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $11.9M | 64 | 21% | N/A | N/A |
What Is Antares Pharma?
Antares Pharma, Inc., develops and commercializes parenteral therapeutic products using advanced drug delivery systems for improved safety and efficacy, reduced side effects, and enhanced patient comfort and adherence. We apply our drug delivery systems in collaborations with pharmaceutical partners to enhance our partners' drug compounds. We believe that we offer a distinct value to patients, physicians, pharmaceutical partners and our shareholders. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. We focus on self-injection pharmaceutical products and technologies and topical gel -based products. Our subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and disposable multi-use pen injectors.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$45M
Total Funding
93
Number of Employees
$63.6M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Antares Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Specialty Sales Representative | Reveal Email/Phone |
2 | Specialty Account Manager | Reveal Email/Phone |
3 | SVP, Device Business and Alliances | Reveal Email/Phone |
4 | VP, Pharmaceutical Development | Reveal Email/Phone |
5 | Accountant | Reveal Email/Phone |
6 | Specialty Account Representative | Reveal Email/Phone |
7 | SVP, Head Commercial | Reveal Email/Phone |
8 | Specialty Account Representative | Reveal Email/Phone |
9 | Director / Head IT | Reveal Email/Phone |
10 | Quality Systems Specialist II | Reveal Email/Phone |
Antares Pharma News
The acquisition will result in the creation of a drug delivery and speciality product company. ... Antares focuses on developing pharmaceutical...
Antares, which was originally founded in Exton, is a specialty pharmaceutical company that develops, manufactures and commercializes therapeutic...
Halozyme Therapeutics Inc. HALO 0.60% agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. ATRS...
ANTARES PHARMA ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR ATRS-1902 FOR ADRENAL CRISIS RESCUE EWING, NJ, July 22, 2021 - Antares Pharma, Inc. (NASDAQ: ATRS) ("the Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted th ...
BNP Paribas Arbitrage SA trimmed its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 43.1% in the second quarter, according to ...
Other Companies in Ewing
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 106 | 0% | N/A |
#2 | $20M | 123 | -8% | N/A |
#3 | $7.5M | 123 | 60% | N/A |
#4 | $548.8M | 204 | 7% | $20.3M |
#5 | $15M | 295 | 1% | N/A |
Antares Pharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-07-16 | $2.0M | Private Placement | Article | |
| 2003-07-23 | $4.0M | Private Placement | Article | |
| 2005-10-20 | $2.0M | Undisclosed | Article | |
| 2006-03-07 | $11.0M | Undisclosed | SCO Securities LLC, Dawson James Securities Inc | Article |
| 2007-03-01 | $10.0M | Undisclosed | MMV Financial Inc, HSBC Capital (Canada) Inc | Article |
| 2007-03-27 | $1.8M | Undisclosed | Bradley Pharmaceuticals Inc | Article |
| 2007-07-02 | $15.0M | Undisclosed | Oppenheimer and Co. Inc | Article |
| 2007-07-11 | $16.0M | Undisclosed | Article | |
| 2009-07-27 | $8.5M | Undisclosed | Cowen Group Inc | Article |
| 2009-07-31 | $Undisclosed | Undisclosed | Cowen and Company LLC | Article |
| 2011-05-19 | $21.4M | Undisclosed | Oppenheimer & Co Inc | Article |
| 2012-10-04 | $47.0M | Undisclosed | Jefferies & Company Inc, Oppenheimer and Co Inc | Article |
| 2015-05-07 | $46.0M | Undisclosed | Piper Jaffray & Co | Article |